Aeolus Pharmaceuticals Announces the Initiation of a Second Study of AEOL 10150 as a Medical Countermeasure for GI Acute Radiation Syndrome Funded by the National Institutes of Health's National Institute for Allergy and Infectious Diseases

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board: AOLS) announced that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract. This study, funded by NIAID, is designed to test the efficacy of AEOL 10150, as measured by survival advantage, as a treatment for damage to the GI tract due to exposure to radiation. If effective, additional studies could be funded to optimize dose and duration of delivery, and to evaluate the window of...

Want to see the full article?

• Purchase this article for only $3.00